Literature DB >> 24150514

The National QAAMS Program - A Practical Example of PoCT Working in the Community.

Mark Ds Shephard1, Janice P Gill.   

Abstract

The Quality Assurance for Aboriginal and Torres Strait Islander Medical Services (QAAMS) Program is the largest and longest-standing national point-of-care testing (PoCT) program in Australia. With a focus on PoCT for diabetes management, it now operates in 115 Indigenous medical services and has been funded continuously by the Australian Government for 11 years. A recent independent evaluation of the QAAMS Program concluded that the program continues to meet best practice standards for Indigenous healthcare, diabetes management and PoCT.

Entities:  

Year:  2010        PMID： 24150514      PMCID： PMC2924122     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN： 0159-8090


  8 in total

1.  The analytical quality of point-of-care testing in the 'QAAMS' model for diabetes management in Australian aboriginal medical services.

Authors:  Mark D S Shephard; Janice P Gill
Journal:  Clin Biochem Rev       Date:  2006-11

2.  Influence of geography on the performance of quality control testing in the Australian Government's point of care testing in general practice trial.

Authors:  Mark D S Shephard
Journal:  Clin Biochem       Date:  2009-05-22       Impact factor: 3.281

3.  Design, implementation and results of the quality control program for the Australian government's point of care testing in general practice trial.

Authors:  Mark Shephard; Anne Shephard; Les Watkinson; Beryl Mazzachi; Paul Worley
Journal:  Ann Clin Biochem       Date:  2009-07-29       Impact factor: 2.057

4.  Results of an innovative education, training and quality assurance program for point-of-care HbA1c testing using the Bayer DCA 2000 in Australian Aboriginal Community Controlled Health Services.

Authors:  Mark D Shephard; Janice P Gill
Journal:  Clin Biochem Rev       Date:  2003-11

5.  Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices.

Authors:  Mark D Shephard; Beryl C Mazzachi; Les Watkinson; Anne K Shephard; Caroline Laurence; Angela Gialamas; Tanya Bubner
Journal:  Rural Remote Health       Date:  2009-08-10       Impact factor: 1.759

6.  Cultural and clinical effectiveness of the 'QAAMS' point-of-care testing model for diabetes management in Australian aboriginal medical services.

Authors:  Mark D S Shephard
Journal:  Clin Biochem Rev       Date:  2006-08

7.  An innovative Australian point-of-care model for urine albumin: creatinine ratio testing that supports diabetes management in indigenous medical services and has international application.

Authors:  M D S Shephard; J P Gill
Journal:  Ann Clin Biochem       Date:  2005-05       Impact factor: 2.057

8.  The impact of point of care testing on diabetes services along Victoria's Mallee Track: results of a community-based diabetes risk assessment and management program.

Authors:  Mark D S Shephard; Beryl C Mazzachi; Anne K Shephard; Kristin J McLaughlin; Bernard Denner; Glennis Barnes
Journal:  Rural Remote Health       Date:  2005-07-15       Impact factor: 1.759
  8 in total
  2 in total

1.  An estimation of the prevalence of diabetes mellitus and diabetic retinopathy in adults in Timor-Leste.

Authors:  Rosie Claire Hewitt Dawkins; Genevieve Frances Oliver; Manoj Sharma; Basilio Martins Pinto; Belmerio Jeronimo; Bernadete Pereira; Julia Magno; Lara Alexandra Motta; Nitin Verma; Mark Shephard
Journal:  BMC Res Notes       Date:  2015-06-18

2.  A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the "TTANGO" trial protocol.

Authors:  Rebecca J Guy; Lisa Natoli; James Ward; Louise Causer; Belinda Hengel; David Whiley; Sepehr N Tabrizi; Basil Donovan; Christopher K Fairley; Steven B Badman; Annie Tangey; Handan Wand; Mark Shephard; David G Regan; David Wilson; David Anderson; John M Kaldor
Journal:  BMC Infect Dis       Date:  2013-10-18       Impact factor: 3.090
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.